

Poster No	Paper Title	Presenting Author
P001	Deep phenotyping of a Thy1-aSyn mouse model of Parkinson's Disease to unravel sex differences	Dr. Elodie Angot
P003	Seeded aggregation of α -synuclein in oligodendrocytes causes synergistic neuronal pathology in vivo	Ms. Anna Barber Janer
P005	Modelling Parkinson's Disease Pathology by Combined Injection of Alpha-Synuclein Preformed Fibrils and Over-Expressing Virus in Mouse Brain	Dr Poonam Thakur
P007	Induction of alpha-synuclein pathology in human iPSC-derived neurospheroids to model synucleinopathies	Dr. Elise Van Breedam
P009	Rpn14/PAAF1 proteasomal chaperone mediates the inhibition of 26S proteasome activity by α -synuclein	Blagovesta Popova
P011	Aberrant sleeping behaviour and inability to perform in object-place recognition task in the (Thy1) ^h [A30P] α -synuclein mouse model	Miss Bernadette Dahl
P013	Modulation of the glucocerebrosidase pathway with ambroxol or GZ667161 attenuates Lewy-like α -synuclein pathology in patient-derived midbrain organoids of GBA1-Parkinson's disease	MD, PhD Emanuele Frattini
P015	The transition of membranous to amyloid-type Lewy bodies in patient-derived neurons	Ms Viktoria Klein
P017	Bivalent cations induce formation of distinct α -Synuclein polymorphs with strain-like properties	Dr. Fatemeh Mamashli
P019	Deep single cell transcriptional profiling of the alpha synuclein 3K aggregation model to identify early alpha synuclein toxicity events	Dr Jimena Monzon Sandoval
P021	The multifaced neuroprotective potential of activin-A in models of Parkinson's disease pathology	Dr Mantia Karampetsou
P023	Ultrastructural analysis of intracellular aggregate morphology in the preformed α -synuclein fibril mouse model	Miss Saskia Manon Drexler

P025	Hypoxia-induced alpha-synuclein alteration impairs cerebrovascular functions in experimental ischemic stroke	Dr. Tizibt Ashine Bogale
P027	Unveiling the role of extracellular vesicles in alpha-Synucleinopathies	Ms. Dimitra Dionysopoulou
P029	Corticostriatal synucleinopathy is associated with cognitive deficits in the rat alpha-synuclein preformed fibril model	Dr Caryl Sortwell
P031	A novel stable human alpha-synuclein transgenic zebrafish line reproducing all the key features of Lewy body disorders since larval stage	Dr Silvia Zini
P033	Characterization of pathology induced by dopaminergic neuron-specific SNCA overexpression by a systemically-delivered AAV-PHP.eB viral construct in adult mice.	Miss Oliana Stange
P035	Silencing of Alpha-Synuclein expression using CRISPRi in mature iPSC-derived Dopaminergic Neurons.	Dr Ana Aragon-Gonzalez
P037	Non-invasive down-regulation of endogenous murine alpha-Synuclein via AAV.PHP.eB-GFP capsids as a novel therapeutic approach for alpha-Synucleinopathies	Ms Elena Gialinaki
P039	Strain-distinct alpha-synuclein and Tau cross-seeding and aggregation in a cell model of synucleinopathies	Dr. Jia-Yi Li
P041	Evaluation of Antisense Oligonucleotides effect on alpha-synuclein pathology in primary enteric cultures from human A53T alpha-synuclein transgenic mice	PhD Fabiana Miraglia
P043	Anxiety and fear related to aSyn pathology in Parkinson's Disease	María Teresa Díaz Santamaría
P045	A Genetic and Connectomic Model for Neural Atrophies Induced by Alpha-Synuclein Injection	Mr. Vikram Nathan
P047	Challenges in replicating brain pathology in a gut-originating mouse model for Parkinson's disease.	Sofie Fouquaert

P049	Seeded aggregation of alpha-synuclein in iPSC-derived brain organoids	Ms Mehtap Bacioglu
P051	Real-time imaging of condensate kinetics reveals α -synuclein amyloid nucleation on the condensate surface	Dr Rebecca Thrush
P053	The Lamprey Giant Synapse model - Probing Alpha-Synuclein localisation at the synapse	Mr Sicheng Han Dr Janin Lautenschläger
P055	Ultrastructural analysis of Lewy bodies in cortical and dopaminergic Neurons in dementia with Lewy bodies and comparing with Parkinson's disease	Ms. Notash Shafiei
P057	PROMISING BIOMARKERS IN MULTIPLE SYSTEM ATROPHY	Phd Samanta Mazzetti
P059	Molecular rotors detect the formation and conversion of α -synuclein oligomers	Ms Siân Allerton
P061	IDENTIFICATION AND PRECLINICAL CHARACTERIZATION OF PET TRACERS FOR IMAGING ALPHA-SYNUCLEIN AGGREGATES IN PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY	Dr Gero Fink
P063	Strain-specific amplification of alpha-synuclein aggregates in vitro	Mr Nicholas Silver
P065	NOVEL SPATIAL TRANSCRIPTOMIC TOOLS TO IDENTIFY CHANGES IN VULNERABLE ANATOMICAL REGIONS AND CELLS IN PARKINSON'S DISEASE	Miss Annie Ziyi Zhao
P067	Comparison of 18F-FP-CIT and 18F-FDOPA PET CT in early Parkinson's disease	MD Sang-Won Yoo
P069	Faecal samples and extracellular vesicles from Parkinson's disease patients show alpha-synuclein seeding capacity	Dr Livia Civitelli
P071	Multimodal autonomic biomarkers differentiate pure autonomic failure from other alpha-synucleinopathies	Dr Giacomo Chiaro
P073	Withdrawn	
P075	Comparison of six monoclonal antibodies anti pSer129- α -synuclein in human skin biopsies: superior sensitivity of the D1R1R with Proteinase K antigen-retrieval	Phd Cecilia Delprete

P077	10-year retrospective study to evaluate the diagnostic relevance in synucleinopathy of skin biopsy from three sites for detecting pSer129- α -synuclein deposits.	Bsc Alex Incensi
P079	Semi-quantitative seed amplification assay for the estimation of α -synuclein seed levels	Ms Carly Farris
P081	pS129 α -synuclein in cerebrospinal fluid and plasma: results of a novel ultrasensitive assay and association with SAA	Mr. Erik Stoops
P083	DETECTION OF PRODROMAL SYNUCLEINOPATHIES USING A HIGHLY SENSITIVE SEEDING AMPLIFICATION IMMUNOASSAY IN IDIOPATHIC REM SLEEP BEHAVIOR DISORDER	Dr. Ilham Abdi
P085	Skin biopsy perspective: a portrait of Parkinson's Disease pathology	Dr. Elena Vacchi
P087	Phosphorylation at Tyrosine 204 is a Marker of ABL1 Activation	Dr Anthony Dossang
P089	Dissecting the differential role of C-terminal truncations in the regulation of aSyn pathology formation and the biogenesis of Lewy bodies	Dr ANNE-LAURE Mahulmellier
P091	Effect of synuclein monomer purification method on consistency of the seed amplification assay	Mr. Zaid Amad Mohammed Al-Azzawi
P093	Characterisation and high-throughput quantification of alpha-synuclein pathology in Alzheimer's disease and dementia with Lewy bodies	Dr Dominik Domanski
P095	Increased soluble high-molecular-weight alpha-synuclein oligomers in dementia with Lewy bodies	Mrs. Mia Antorini
P097	Alpha-Synuclein-Induced Neuronal Damage as a Key Driver of Neurodegeneration in MSA	Dr Victor Dieriks
P099	The complexities of PINK1 Parkinson's disease; A Meta-Analysis of α -Synuclein Pathology, Prevalence, and Phenotypic Variability	Miss Eden Paige Yin
P101	Structure-function relationship of α -Synuclein	Malavika Sriram

P103	Solid-state NMR structure of A30P alpha-synuclein fibrils and objective structural polymorph classification	Mr Moses Milchberg
P105	Acetylated α -tubulin and α -synuclein in Parkinson's disease: region-specific changes in post-mortem human brain	PhD Graziella Cappelletti
P107	Targeting alpha-synuclein with the lipoxygenase inhibitor PTC-041 as a therapeutic approach for the treatment of Parkinson's disease	Dr Angela Minnella
P109	Elucidating the Molecular Mechanisms of α -Synuclein Liquid-Liquid Phase Separation by Mass Spectrometry	Ms Wiebke Franziska Günther
P111	Unveiling the nuclear physiological role of α -Synuclein	Dr Sivaraman Padavattan
P113	Role of aSYN S129 phosphorylation on VAMP2-mediated aSYN phase separation	Miss Shiyue Chen
P115	G6PD is a risk allele for the initiation of Parkinson's Disease	Ms. Shehani Siripala
P117	VAMP2 promotes lipid-dependent phase separation of alpha-synuclein	Dr. Aishwarya Agarwal
P119	Rethinking α -Synuclein: How SNCA disease variants affect phase separation	Dr Aswathy Chandran
P121	α -Synuclein G6PD interaction suggests a direct role for α -Synuclein in the regulation of the metabolism	Msc Suelen Camargo
P123	Withdrawn	
P125	ACI-21018, a small molecule inhibitor targeting a-synuclein pathology	Dr. Nadine Ait-Bouziad
P127	A Gene Therapy Approach Targeting alpha-Synuclein To Halt the Progression of Parkinson's disease	Mr. Ayman Faroqi
P129	Development and evaluation of SPK-10005, an AAV-miRNA-based gene therapy targeting and reducing human alpha-synuclein	Dr Vikrant Singh
P131	Results from ORCHESTRA, a Phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage PD	Dr Zahid Ali

P133	Targeting the Serca transporter to restore neuronal Ca ²⁺ balance: a new approach for Parkinson's disease treatment	Lasse Reimer Dr Zagorka Vitic
P135	SNCA duplication induces neurite degeneration via cytoskeletal disruption in Parkinson's disease patient-derived midbrain neurons	Prof. Dr. Wei Xiang
P137	Investigating the neurotoxic effects of the A30G α -synuclein mutation in <i>C. elegans</i>	Dr Konstantinos Palikaras
P139	The overexpression and spread of neuronal α -Synuclein to astrocytes differentially affects mitochondrial function in vitro	Dr. Virginia Solar Fernández
P141	The inflammatory signature of Parkinson's disease using deep learning and spatial tools	Dr David Menassa
P143	REVEALING ALTERATIONS IN PROTEASOME AND IMMUNE RESPONSE IN SUBSTANTIA NIGRA OF PARKINSON'S DISEASE: INSIGHTS FROM GEO DATABASE AND EXPERIMENTAL MODELS	Ms Thi Len Ho
P145	Therapeutic targeting of NLRP3 inflammasome with Dapansutril in a transgenic mouse model of multiple system atrophy	MSc Magdalena Matic
P147	Characterizing immune alterations in a male and female rat model of Parkinson's disease through Single-cell RNA sequencing	Sara A. Ferreira
P149	Exposure to bacterial amyloid curli primes immune cells in response to α -synuclein	Dr Neha Jain
P151	Linking pathological α Synuclein-mediated synaptopathy and neurodegeneration to maternal immune activation	Dr Era Taoufik
P153	SARS-CoV-2 Spike Protein Induces Alpha-Synuclein Accumulation and Neuroinflammation in Parkinson's Disease-Relevant Brain Regions	DVM PHD Christopher Kaeufer
P155	Cross-talk of gut-brain immune interactions in α -synuclein aggregation and propagation	Dr. Haowen Dou

P157	Aspirin and ibuprofen counteract pathology triggered by preformed alpha-synuclein fibrils in vivo	Dr Eva M. Szegö
P159	The alpha-synuclein proteostasis network and its links with Parkinson's disease	Miss Christine Maria Lim
P161	Synthesis and validation of PROTACs for ubiquitin-mediated degradation of alpha-synuclein aggregates in cellular models of Parkinson's disease	Dr. Taniya Bhardwaj
P163	Alpha synuclein, TPPP/p25 α and MAPT/tau at the crossroads of Multiple System Atrophy pathogenesis	Miss Stamatia Loulouda
P165	The chaperone Clusterin: a player in alpha-Synuclein aggregation in Parkinson's disease human brain?	Dr Giovanni Zanchi
P167	Penetratin prevents α -synuclein fibrillation and associated neurodegeneration in mouse model of Parkinson's disease	Dr. Deepak Sharma (attendance sponsored by the Lewy Body Society)
P169	Investigation of alpha-synuclein levels in an animal model of absence epilepsy	Prof Filiz Onat
P171	Drivers of pathology progression – Investigating cellular vulnerability factors using the preformed α -synuclein fibril mouse model	Mr Ahmed Algali Sedahmed Musa
P173	Injection of α -Syn assemblies induces early motor deficits in M83 mice; Involvement of the gap-junction protein Cx32 in α -Syn spreading	Dr. Juan F Reyes
P175	The expression of a-synuclein oligomeric forms of skeletal muscle rises with aging.	Prof.Dr. Alicia Ortega
LB01	Pathological aggregates induce gel-like proteasome condensates that facilitate degradation of protein aggregates	Dr Yu Ye
LB03	Large rodent model: organisation of the main olfactory bulb and immunoreactivity of tyrosine hydroxylase, calretinin, and alpha-synuclein in the paca (Cuniculus	Silvio Pires Gomes
LB05	Repositioning of immunomodulatory drugs to arrest alpha-synuclein neuropathology	Prof Anna Carta